Matches in SemOpenAlex for { <https://semopenalex.org/work/W3102203412> ?p ?o ?g. }
- W3102203412 abstract "Introduction: Chronic kidney disease (CKD) is common among patients undergoing lower extremity revascularization (LER) for peripheral artery disease (PAD) and identifies a population at high risk for adverse outcomes. The VOYAGER PAD trial demonstrated the efficacy of rivaroxaban in PAD patients after LER on a composite of cardiovascular (CV) and limb ischemic events (HR 0.85 vs placebo, 95% CI 0.76-0.96; p=0.009); this analysis examines the prespecified subgroup of patients with CKD. Methods: VOYAGER PAD (NCT02504216) was a double-blind, placebo-controlled trial which randomized PAD patients with recent LER to rivaroxaban 2.5 mg twice daily or placebo on a background of aspirin 100 mg daily. The primary endpoint was a composite of acute limb ischemia, major amputation for vascular cause, myocardial infarction, ischemic stroke or CV death. The primary safety endpoint was TIMI major bleeding. Analysis of the intention-to-treat population utilized Kaplan Meier estimates and Cox proportional-hazards models. Results: Among 6319 VOYAGER patients with baseline estimated glomerular filtration rate (eGFR), 21% were <60 (mostly CKD stage 3) and 79% were ≥60 ml/min/1.73m 2 . During 28-month (median) follow up, patients with CKD had a higher rate of major CV and limb events: placebo group 10.0 events/100 patient-years (95% CI 8.5, 11.8) for eGFR <60 vs 7.4 (95% CI 6.7, 8.2) for eGFR ≥60. Rivaroxaban reduced primary outcome events with no heterogeneity by eGFR category (Figure, p for interaction 0.62). Acute limb ischemia and major amputation were significantly reduced among patients with eGFR<60 (HR 0.55, 95% CI 0.36, 0.86) as well as ≥60 (HR 0.77, 95% CI 0.63, 0.94). TIMI major bleeding was numerically more frequent among patients with CKD with no heterogeneity by treatment group (Figure, p for interaction 0.37). Conclusions: Rivaroxaban reduced major CV and limb events in patients with PAD undergoing LER, including those with CKD, a particularly high-risk population." @default.
- W3102203412 created "2020-11-23" @default.
- W3102203412 creator A5006707490 @default.
- W3102203412 creator A5008902742 @default.
- W3102203412 creator A5014777482 @default.
- W3102203412 creator A5027693791 @default.
- W3102203412 creator A5029772859 @default.
- W3102203412 creator A5038981448 @default.
- W3102203412 creator A5051784294 @default.
- W3102203412 creator A5054781690 @default.
- W3102203412 creator A5055052720 @default.
- W3102203412 creator A5058205892 @default.
- W3102203412 creator A5072997191 @default.
- W3102203412 creator A5076746946 @default.
- W3102203412 creator A5089208862 @default.
- W3102203412 creator A5090903599 @default.
- W3102203412 date "2020-11-17" @default.
- W3102203412 modified "2023-10-18" @default.
- W3102203412 title "Abstract 13474: Rivaroxaban Reduces Major Cardiovascular and Limb Events in Patients With the High-risk Triad of Chronic Kidney Disease, Peripheral Artery Disease and Recent Lower Extremity Revascularization: Insights From VOYAGER PAD" @default.
- W3102203412 doi "https://doi.org/10.1161/circ.142.suppl_3.13474" @default.
- W3102203412 hasPublicationYear "2020" @default.
- W3102203412 type Work @default.
- W3102203412 sameAs 3102203412 @default.
- W3102203412 citedByCount "0" @default.
- W3102203412 crossrefType "journal-article" @default.
- W3102203412 hasAuthorship W3102203412A5006707490 @default.
- W3102203412 hasAuthorship W3102203412A5008902742 @default.
- W3102203412 hasAuthorship W3102203412A5014777482 @default.
- W3102203412 hasAuthorship W3102203412A5027693791 @default.
- W3102203412 hasAuthorship W3102203412A5029772859 @default.
- W3102203412 hasAuthorship W3102203412A5038981448 @default.
- W3102203412 hasAuthorship W3102203412A5051784294 @default.
- W3102203412 hasAuthorship W3102203412A5054781690 @default.
- W3102203412 hasAuthorship W3102203412A5055052720 @default.
- W3102203412 hasAuthorship W3102203412A5058205892 @default.
- W3102203412 hasAuthorship W3102203412A5072997191 @default.
- W3102203412 hasAuthorship W3102203412A5076746946 @default.
- W3102203412 hasAuthorship W3102203412A5089208862 @default.
- W3102203412 hasAuthorship W3102203412A5090903599 @default.
- W3102203412 hasConcept C126322002 @default.
- W3102203412 hasConcept C127413603 @default.
- W3102203412 hasConcept C141071460 @default.
- W3102203412 hasConcept C142724271 @default.
- W3102203412 hasConcept C164705383 @default.
- W3102203412 hasConcept C168563851 @default.
- W3102203412 hasConcept C203092338 @default.
- W3102203412 hasConcept C204787440 @default.
- W3102203412 hasConcept C207103383 @default.
- W3102203412 hasConcept C27081682 @default.
- W3102203412 hasConcept C2776301958 @default.
- W3102203412 hasConcept C2777466421 @default.
- W3102203412 hasConcept C2777628954 @default.
- W3102203412 hasConcept C2778653478 @default.
- W3102203412 hasConcept C2778661090 @default.
- W3102203412 hasConcept C2778963770 @default.
- W3102203412 hasConcept C2779161974 @default.
- W3102203412 hasConcept C2779464278 @default.
- W3102203412 hasConcept C2780645631 @default.
- W3102203412 hasConcept C2781099653 @default.
- W3102203412 hasConcept C2908647359 @default.
- W3102203412 hasConcept C3018348675 @default.
- W3102203412 hasConcept C44249647 @default.
- W3102203412 hasConcept C500558357 @default.
- W3102203412 hasConcept C71924100 @default.
- W3102203412 hasConcept C78519656 @default.
- W3102203412 hasConcept C99454951 @default.
- W3102203412 hasConceptScore W3102203412C126322002 @default.
- W3102203412 hasConceptScore W3102203412C127413603 @default.
- W3102203412 hasConceptScore W3102203412C141071460 @default.
- W3102203412 hasConceptScore W3102203412C142724271 @default.
- W3102203412 hasConceptScore W3102203412C164705383 @default.
- W3102203412 hasConceptScore W3102203412C168563851 @default.
- W3102203412 hasConceptScore W3102203412C203092338 @default.
- W3102203412 hasConceptScore W3102203412C204787440 @default.
- W3102203412 hasConceptScore W3102203412C207103383 @default.
- W3102203412 hasConceptScore W3102203412C27081682 @default.
- W3102203412 hasConceptScore W3102203412C2776301958 @default.
- W3102203412 hasConceptScore W3102203412C2777466421 @default.
- W3102203412 hasConceptScore W3102203412C2777628954 @default.
- W3102203412 hasConceptScore W3102203412C2778653478 @default.
- W3102203412 hasConceptScore W3102203412C2778661090 @default.
- W3102203412 hasConceptScore W3102203412C2778963770 @default.
- W3102203412 hasConceptScore W3102203412C2779161974 @default.
- W3102203412 hasConceptScore W3102203412C2779464278 @default.
- W3102203412 hasConceptScore W3102203412C2780645631 @default.
- W3102203412 hasConceptScore W3102203412C2781099653 @default.
- W3102203412 hasConceptScore W3102203412C2908647359 @default.
- W3102203412 hasConceptScore W3102203412C3018348675 @default.
- W3102203412 hasConceptScore W3102203412C44249647 @default.
- W3102203412 hasConceptScore W3102203412C500558357 @default.
- W3102203412 hasConceptScore W3102203412C71924100 @default.
- W3102203412 hasConceptScore W3102203412C78519656 @default.
- W3102203412 hasConceptScore W3102203412C99454951 @default.
- W3102203412 hasIssue "Suppl_3" @default.
- W3102203412 hasLocation W31022034121 @default.
- W3102203412 hasOpenAccess W3102203412 @default.
- W3102203412 hasPrimaryLocation W31022034121 @default.
- W3102203412 hasRelatedWork W2089715561 @default.
- W3102203412 hasRelatedWork W2155730805 @default.
- W3102203412 hasRelatedWork W2404680446 @default.